Presentation is loading. Please wait.

Presentation is loading. Please wait.

Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). Classification tree for subgroups of idiopathic inflammatory myopathies.

Published byMats Lindgren Modified over 5 years ago

Similar presentations

Presentation on theme: "Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). Classification tree for subgroups of idiopathic inflammatory myopathies."— Presentation transcript:

1 Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs).
Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). A patient must first be classified as having IIM using the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria. The patient can then be subclassified using the classification tree. The mixed (dotted outlined box) subgroup of patients with PM includes patients with IMNM. For IBM diagnosis, one of the following, *Finger flexor weakness and response to treatment: not improved or **Muscle biopsy: rimmed vacuoles, is required for diagnosis. ***Juvenile myositis other than JDM was developed based on expert opinion and extrapolation from adults. IMNM and hypomyopathic DM were too few to allow subclassification. ADM, amyopathic dermatomyositis; DM, dermatomyositis; IBM, inclusion body myositis; IMNM, immune-mediated necrotising myopathy; JDM, juvenile dermatomyositis; PM, polymyositis. Matteo Bottai et al. RMD Open 2017;3:e000507 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). Classification tree for subgroups of idiopathic inflammatory myopathies."

Similar presentations

Autoantibodies in PM and DM Autoantibodies:>90% Autoantibodies:>90% Positive ANA:60-80% Positive ANA:60-80%  More in overlap  Low in IBM Defined antibodies:50%

Autoantibodies in PM and DM Autoantibodies:>90% Autoantibodies:>90% Positive ANA:60-80% Positive ANA:60-80%  More in overlap  Low in IBM Defined antibodies:50%
IMACS History and Development of Myositis Clinical Trials Muscle Study Group September 21, 2010 Chester V. Oddis, MD University of Pittsburgh.

IMACS History and Development of Myositis Clinical Trials Muscle Study Group September 21, 2010 Chester V. Oddis, MD University of Pittsburgh.
Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies
Dr Chandrashekara S Medical Director

Dr Chandrashekara S Medical Director
Diagnosis and Management of Immune-Mediated Myopathies

Diagnosis and Management of Immune-Mediated Myopathies
The genomic region spanning rs shows enhancer activity.

The genomic region spanning rs shows enhancer activity.
Anti-Synthetase Syndrome

Anti-Synthetase Syndrome
Dermatomyositis perifascicular pattern of involvement

Dermatomyositis perifascicular pattern of involvement
NP17-938 D.P. Bx: 9/8/2017.

NP D.P. Bx: 9/8/2017.
European League Against Rheumatism/American College of Rheumatology classification criteria probability of having idiopathic inflammatory myopathies (IIMs)

European League Against Rheumatism/American College of Rheumatology classification criteria probability of having idiopathic inflammatory myopathies (IIMs)
Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations  Floranne C. Ernste, MD,

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations  Floranne C. Ernste, MD,
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.

VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Similar presentations

Ads by Google